Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 13/20 | 0.72 |
| ▸ | LTB4R2 | Q9NPC1 | 9/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844 | 1.00 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2966050 | 0.95 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL29406387 | 0.92 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL12600308 | 0.92 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL13816890 | 0.92 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL2542 | 0.92 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL157179 | 0.92 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL2329 | 0.92 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL21408288 | 0.92 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 | |
| Valsartan SCHEMBL1560689 | 0.92 | AGTR1 (0.72) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | claimed |
| US-10010529-B2 | Extended release pharmaceutical formulations with controlled impurity levels | EZRA PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010529-B2 | Extended release pharmaceutical formulations with controlled impurity levels | EZRA PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170290805-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS WITH CONTROLLED IMPURITY LEVELS | EZRA PHARMA LLC (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290805-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS WITH CONTROLLED IMPURITY LEVELS | EZRA PHARMA LLC (US) | 2017-10-12 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290805-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS WITH CONTROLLED IMPURITY LEVELS | REN, ACE, AGTR1 | AGTR1 3/4885LTB4R2 2947/4885ABCB11 156/4885 |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | AGTR1 3252/4885LTB4R2 609/4885ABCB11 4659/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR1 8/4885LTB4R2 254/4885ABCB11 4566/4885 |
| US-10010529-B2 | Extended release pharmaceutical formulations with controlled impurity levels | REN, ACE, AGTR1 | AGTR1 3/4885LTB4R2 2947/4885ABCB11 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.